CHEMORADIOTHERAPY FOR RECTAL CANCER IN THE DISTAL RECTUM FOLLOWED BY ORGANSPARING TRANSANAL ENDOSCOPIC MICROSURGERY: CARTS Study CApecitabine, Radiotherapy and Tem Surgery. A PHASE II, FEASIBILITY TRIAL
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 17
- 主要终点
- Response
研究概览
简要总结
In the Netherlands approximately 2300 new patients are diagnosed with rectal cancer each year. Standard treatment for patients with a T2 or T3 rectal cancer consists of preoperative short course of radiotherapy followed by surgery. In advanced cases long course of radiotherapy combined with chemotherapy is used instead of a short cause. In some of these advanced cases a complete remission is observed after a long course of radio-/chemotherapy. Patients who respond well to neo-adjuvant treatment carry a better prognosis.
Objective of this research is to evaluate whether neo-adjuvant chemo-/radiotherapy in small non-advanced rectal cancers can be used to obtain a complete or near complete remission. In these patients could a complete resection of the rectum as an organ be avoided by treating them with a local excision with the TEM-technique (Transanal Endoscopic Microsurgery) of the scar. The advantage for these patients is, that they do not need major abdominal surgery and in a substantial number of these patients the rectum can be preserved with a better function of continence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients (aged >18 years) with histological proven adenocarcinoma of the distal part of the rectum (below 10 cm) without signs of distant metastases.
- •T1-3 tumour without lymph nodes > 5 mm at CT, MRI and endoanal ultrasound.
- •ANC > 1.5 x 109/l.
- •Thrombocytes > 100 x 109/l.
- •Creatinin clearance >50ml/min (according to the Cockcroft-Gault formula)
- •Total serum bilirubin < 24 mol/l or below <1.5 times the upper limit of the normal.
- •ASAT,ALAT: up to 5 times the upper limit.
- •Colonoscopy, colonography or virtual colonoscopy should exclude synchronous colorectal lesions in other parts of the colon.
- •ECOG performance score 0-
- •Fertile women should have adequate birth control during treatment.
- •Mental/physical/geographical ability to undergo treatment and follow-up.
- •Written informed consent (Dutch language).
排除标准
- •Patients with Grade 1-2 T1 tumors (can be treated with TEM surgery without chemoradiation therapy)
- •Patients with circular rectal tumor or tumors who are by other means unacceptable for TEM surgery (e.g. intra anal tumors).
- •Patients with faecal incontinence prior to the diagnosis of rectal cancer (complaints of soiling due to the tumor will not be an exclusion criterium).
- •Severe uncontrollable medical or neurological disease.
- •Patients with secondary prognosis determining malignancies.
- •Patients who have been treated with radiotherapy on the pelvis.
- •Use of Vitamin K antagonists.
- •Fenytoine and Allopurinol use.
- •Known DPD deficiency
- •Uncontrolled active infection, compromised immune status, psychosis, or CNS disease.
- •Pregnant or lactating women.
- •Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤ 6 months prior to randomisation), myocardial infarction (≤ 6 months prior to randomisation), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication.
- •Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of Capecitabine or patients at high risk for treatment complications. History or evidence upon physical examination of CNS disease unless adequately treated (e.g., seizure not controlled with standard medical therapy).
结局指标
主要结局
Response
时间窗: Baseline and 6 weeks after chemoradiation therapy
the response of the rectal carcinoma to chemo-/radiotherapy defined as complete response (no visible disease); partial response (more than 50% reduction of the tumour mass); no response (meaning an increase of the tumour mass less than 25% or a decrease of the tumour mass less than 50%); or progressive disease when the tumour mass increase more than 25% of the original tumour mass.
次要结局
- The number of sphincter saving procedures(4 weeks after surgery last enrolled patient)
- Local Recurrence(36 months, 60 months after surgery last enrolled patient)
- Number of positive lymph nodes in patient who have been treated with classical surgery(4 weeks after surgery last enrolled patient)
- Quality of life(baseline, 6-12-24 and 35 months after surgery)
- Toxicity(4 weeks after surgery last enrolled patient)